Shanghai - Delayed Quote CNY

Hangzhou Biotest Biotech Co.,Ltd. (688767.SS)

25.19 +0.19 (+0.76%)
At close: 3:00 PM GMT+8
Loading Chart for 688767.SS
DELL
  • Previous Close 25.00
  • Open 24.95
  • Bid 25.12 x --
  • Ask 25.19 x --
  • Day's Range 24.91 - 25.23
  • 52 Week Range 22.23 - 39.63
  • Volume 186,548
  • Avg. Volume 445,244
  • Market Cap (intraday) 2.687B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) --
  • EPS (TTM) -0.18
  • Earnings Date --
  • Forward Dividend & Yield 2.20 (8.80%)
  • Ex-Dividend Date Jun 9, 2023
  • 1y Target Est --

Hangzhou Biotest Biotech Co., LTD. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. The company was founded in 2008 and is based in Hangzhou, China.

www.biotests.com.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 688767.SS

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

688767.SS
16.78%
SSE Composite Index
2.62%

1-Year Return

688767.SS
34.26%
SSE Composite Index
6.79%

3-Year Return

688767.SS
--
SSE Composite Index
16.93%

5-Year Return

688767.SS
--
SSE Composite Index
16.93%

Compare To: 688767.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688767.SS

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    2.67B

  • Enterprise Value

    804.18M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.83

  • Price/Book (mrq)

    1.10

  • Enterprise Value/Revenue

    1.76

  • Enterprise Value/EBITDA

    14.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.15%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    4.46%

  • Revenue (ttm)

    442.36M

  • Net Income Avi to Common (ttm)

    111.27M

  • Diluted EPS (ttm)

    -0.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.87B

  • Total Debt/Equity (mrq)

    0.14%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: 688767.SS

People Also Watch